½ÃÀ庸°í¼­
»óǰÄÚµå
1679344

°£¾Ï Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Ä¡·áº°, À¯Çüº°, À¯Åë ä³Îº°, Áö¿ªº°(2025-2030³â)

Liver Cancer Drug Market Size, Share & Trends Analysis Report By Therapy, By Type, By Distribution Channel, By Region, And Segment Forecasts 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 100 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

°£¾Ï Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀå ¹× µ¿Çâ

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°èÀÇ °£¾Ï Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 98¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í, 2025-2030³â CAGR 17.9%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. °£¾Ï ½ÃÀåÀÇ ¼ºÀåÀº ÁÖ·Î ½Å¾àÀÇ °¡¿ë¼º, °­·ÂÇÑ ÆÄÀÌÇÁ¶óÀÎÀÇ Á¸Àç, ´ëÁßÀÇ ÀÎ½Ä »ó½Â°ú °°Àº ¿äÀο¡ ÀÇÇØ ÁÖµµµË´Ï´Ù. °£¾Ï ȯÀÚÀÇ Àúº¯ È®´ë´Â °Ç°­¿¡ ÇØ·Î¿î »ýȰ ¹æ½Ä°ú ³ëÀÎ Àα¸ Áõ°¡¿¡ ±âÀÎ ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ´Â °á±¹ °£¾Ï Ä¡·áÁ¦ ½ÃÀå¿¡ À¯¸®ÇÏ°Ô ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ³Ø»ç¹Ù ºÒ³»¼º ȯÀÚ¸¦ À§ÇÑ 2Â÷ Ä¡·á¹ý °³¹ßÀº °£¼¼Æ÷¾Ï ºÐ¾ß¿¡¼­ Å« ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°£¾ÏÀº Àü ¼¼°è¿¡¼­ ´Ù¼¸ ¹øÂ°·Î ¸¹ÀÌ ¹ß»ýÇÏ´Â ¾ÏÀ¸·Î Àüü ¾Ï »ç¸ÁÀÇ 9.0%¸¦ Â÷ÁöÇÕ´Ï´Ù. 2012³â¿¡´Â 782,451¸íÀÌ »õ·Ó°Ô °£¾ÏÀ¸·Î Áø´ÜµÇ¾úÀ¸¸ç, 74¸¸ 5,533¸íÀÌ °£¾ÏÀ¸·Î »ç¸ÁÇÑ °ÍÀ¸·Î º¸°íµÇ¾ú½À´Ï´Ù. ¿ø¹ß¼º °£¾ÏÀº ¸Å¿ì °ø°ÝÀûÀΠƯ¼º°ú ³·Àº »ýÁ¸À²·Î ÀÎÇØ ¿©ÀüÈ÷ Áß¿äÇÑ °øÁß º¸°Ç ¹®Á¦·Î ³²¾Æ ÀÖ½À´Ï´Ù. °£¼¼Æ÷¾Ï(HCC)Àº ¿ø¹ß¼º °£¾ÏÀÇ ´ëºÎºÐ(75-90%)À» Â÷ÁöÇÕ´Ï´Ù. °¨¿° ¹× °£°æº¯À» Æ÷ÇÔÇÑ °£¾ÏÀÇ ÁÖ¸ñÇÒ¸¸ÇÑ º´ÀÎ ¿äÀÎÀº »ýȰ ½À°ü ±³Á¤ ¹× °£¿° ¿¹¹æ Á¢Á¾°ú °°Àº ¿¹¹æ Àü·«À» ÅëÇØ ¹ßº´·ü°ú »ç¸Á·üÀ» ³·Ãâ ¼ö ÀÖ´Â °­·ÂÇÑ Àü¸ÁÀ» Á¦½ÃÇÒ ¼ö ÀÖ½À´Ï´Ù.

°£¾Ï Ä¡·áÁ¦ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • Ç¥Àû Ä¡·á ºÎ¹®Àº ¾Ï¼¼Æ÷ÀÇ ¼ºÀå ¹× È®»ê¿¡ °ü¿©Çϴ ƯÁ¤ ºÐÀÚ ¶Ç´Â °æ·Î¸¦ Ç¥ÀûÀ¸·ÎÇÏ´Â Á¤¹Ð¼ºÀ¸·Î ÀÎÇØ 2024³â¿¡ 53.1%ÀÇ °¡Àå Å« ½ÃÀå ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • °£¼¼Æ÷¾Ï(HCC)Àº 2024³â 38.2%ÀÇ ¸ÅÃâ Á¡À¯À²·Î °£¾Ï Ä¡·áÁ¦ ½ÃÀåÀ» Áö¹èÇß½À´Ï´Ù. °£¼¼Æ÷¾ÏÀº °¡Àå ÈçÇÑ À¯ÇüÀÇ ¿ø¹ß¼º °£¾ÏÀÔ´Ï´Ù.
  • º´¿ø ¾à±¹Àº 2024³â 45.7%ÀÇ ¸ÅÃâ Á¡À¯À²·Î °£¾Ï Ä¡·áÁ¦ ½ÃÀåÀ» Áö¹èÇß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå °£¾Ï Ä¡·áÁ¦ ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅëÀÇ Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ºñÁî´Ï½º ȯ°æ ºÐ¼®
    • »ê¾÷ ºÐ¼® - Porter's Five Forces ºÐ¼®
    • PESTLE ºÐ¼®
    • ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®

Á¦4Àå °£¾Ï Ä¡·áÁ¦ ½ÃÀå : Ä¡·áº° ºñÁî´Ï½º ºÐ¼®

  • Ä¡·áº° ½ÃÀå Á¡À¯À²(2024³â, 2030³â)
  • Ä¡·á ºÎ¹® ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®, Ä¡·áº°(2018-2030³â)
  • Ç¥Àû Ä¡·á
  • ¸é¿ª Ä¡·á
  • È­ÇÐ Ä¡·á
  • ±âŸ

Á¦5Àå °£¾Ï Ä¡·áÁ¦ ½ÃÀå : À¯Çüº° ºñÁî´Ï½º ºÐ¼®

  • À¯Çüº° ½ÃÀå Á¡À¯À²(2024³â, 2030³â)
  • À¯Çü ºÎ¹® ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®, À¯Çüº°(2018-2030³â)
  • °£¼¼Æ÷¾Ï
  • ´ã°ü¾Ï
  • °£ ¸ð¼¼Æ÷Á¾
  • ±âŸ

Á¦6Àå °£¾Ï Ä¡·áÁ¦ ½ÃÀå : À¯Åë ä³Îº° ºñÁî´Ï½º ºÐ¼®

  • À¯Åë ä³Îº° ½ÃÀå Á¡À¯À²(2024³â, 2030³â)
  • À¯Åë ä³Î ºÎ¹® ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®, À¯Åë ä³Îº°(2018-2030³â)
  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦7Àå °£¾Ï Ä¡·áÁ¦ ½ÃÀå : Áö¿ªº°, ÃßÁ¤ ¹× µ¿Ç⠺м®

  • Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â, 2030³â)
  • Áö¿ªº° ½ÃÀå ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø µ¿Ç⠺м®(2018-2030³â)
  • ºÏ¹Ì
    • ±¹°¡º°(2018-2030³â)
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • ±¹°¡º°(2018-2030³â)
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ±¹°¡º°(2018-2030³â)
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ±¹°¡º°(2018-2030³â)
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ±¹°¡º°(2018-2030³â)
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • Äí¿þÀÌÆ®

Á¦8Àå °æÀï ±¸µµ

  • Âü°¡ÀÚ °³¿ä
  • ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´× ºÐ¼®
  • ±â¾÷ ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ ¹× »óÀå ±â¾÷
    • Exelixis, Inc.
    • Merck KGaA
    • Eisai Co., Ltd.
    • Bristol-Myers Squibb Company
    • Thermo Fisher Scientific Inc.
    • Pfizer Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Bayer AG
HBR 25.04.11

Liver Cancer Drug Market Growth & Trends:

The global liver cancer drug market size is anticipated to reach USD 9.81 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 17.9% from 2025 to 2030. The growth of liver cancer market is largely driven by factors such as availability of novel drugs, presence of strong pipeline, and rising public awareness. Widening base of liver cancer patients can be attributed to unhealthy lifestyles and growing geriatric population. This, in turn, is working in favor of the liver cancer therapeutics market. Therapeutic development in second-line setting for Nexavar-intolerant patients is estimated to have a major impact in the HCC space.

Liver cancer is the fifth most prevalent cancer worldwide and accounts for 9.0% of all cancer deaths. In 2012, 782,451 new cases of liver cancer were diagnosed, and 745,533 deaths were reported due to liver cancer. Primary liver cancer remains an important public health issue due to its extremely aggressive nature and poor survival rate. Hepatocellular carcinomas (HCCs) represents the majority (75-90%) of primary liver cancers. A noteworthy number of etiological factors of liver cancer, including hepatitis infection and cirrhosis, can be modified and present a strong prospect to reduce its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization.

Liver Cancer Drug Market Report Highlights:

  • The targeted therapy segment held the largest market revenue share of 53.1% in 2024 due to its precision in targeting specific molecules or pathways involved in the growth and spread of cancer cells.
  • Hepatocellular Carcinoma (HCC) dominated the liver cancer drug market with a 38.2% revenue share in 2024. HCC Is the most common type of primary liver cancer.
  • Hospital pharmacy dominated the liver cancer drug market with a revenue share of 45.7% in 2024.
  • North America liver cancer drug market held a revenue share of 38.7% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapy
    • 1.2.2. Type
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Liver Cancer Drug Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Liver Cancer Drug Market: Therapy Business Analysis

  • 4.1. Therapy Market Share, 2024 & 2030
  • 4.2. Therapy Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
  • 4.4. Targeted Therapy
    • 4.4.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
  • 4.5. Immunotherapy
    • 4.5.1. Immunotherapy Market, 2018 - 2030 (USD Million)
  • 4.6. Chemotherapy
    • 4.6.1. Chemotherapy Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Liver Cancer Drug Market: Type Business Analysis

  • 5.1. Type Market Share, 2024 & 2030
  • 5.2. Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. Hepatocellular Carcinoma
    • 5.4.1. Hepatocellular Carcinoma Market, 2018 - 2030 (USD Million)
  • 5.5. Cholangio Carcinoma
    • 5.5.1. Cholangio Carcinoma Market, 2018 - 2030 (USD Million)
  • 5.6. Hepatoblastoma
    • 5.6.1. Hepatoblastoma Market, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Liver Cancer Drug Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Liver Cancer Drug Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Liver Cancer Drug Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Liver Cancer Drug Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.5.2. Germany
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. Germany Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. UK
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. UK Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Denmark Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Sweden Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Norway Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Liver Cancer Drug Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. Australia Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. South Korea Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Liver Cancer Drug Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Liver Cancer Drug Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Exelixis, Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Merck KGaA
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Eisai Co., Ltd.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Bristol-Myers Squibb Company
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Thermo Fisher Scientific Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Pfizer Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Eli Lilly and Company
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. F. Hoffmann-La Roche Ltd
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Novartis AG
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Bayer AG
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦